The stock spiked 14.53% last month and is up 8.56 this year. (NYSE:WMB) recently saw its volume around 5.63 million shares and on average it trades 5.31 million shares a day. (NYSE:HD) has risen 18.65% since January 12, 2017 and is uptrending. It has outperformed by 6.87% the S&P500. Municipal Employees Retirement System of MI lifted its holdings in Progenics Pharmaceuticals by 4.0% during the 2nd quarter. 740,856 shares of the stock were exchanged, compared to its average volume of 1,360,000. The hedge fund run by Philip Hempleman held 1.91M shares of the major pharmaceuticals company at the end of 2017Q3, valued at $14.06 million, up from 510,000 at the end of the previous reported quarter.
Progenics Pharmaceuticals (NASDAQ PGNX) traded up $0.02 during midday trading on Thursday, hitting $6.34. Fmr Ltd Liability accumulated 2.45 million shares. Cantor Fitzgerald set a $15.00 price objective on shares of Progenics Pharmaceuticals and gave the stock a "buy" rating in a research note on Tuesday, January 2nd. It has outperformed by 31.71% the S&P500. It also reduced its holding in Kilroy Rlty Corp (NYSE:KRC) by 20,000 shares in the quarter, leaving it with 113,900 shares, and cut its stake in Caterpillar Inc Del (NYSE:CAT).
The Williams Companies, Inc. has a consensus outperform rating from 21 Wall Street analysts, and the number of shares now sold short amount to at least 1.97% of shares outstanding. CIGNA had 53 analyst reports since July 27, 2015 according to SRatingsIntel. Jefferies upgraded the stock to "Buy" rating in Friday, October 23 report. During last 3 month period, 0.02% of total institutional ownership has changed in the company shares. RBC Capital Markets maintained Cigna Corporation (NYSE:CI) rating on Monday, November 9. (NYSE:HD), 24 have Buy rating, 0 Sell and 9 Hold. Bnp Paribas Arbitrage reported 35,323 shares.
Since August 7, 2017, it had 0 insider buys, and 7 insider sales for $8.11 million activity. Shares for $402,366 were sold by Bacus Lisa R. Another trade for 1,232 shares valued at $230,662 was made by ZOLLARS WILLIAM D on Wednesday, September 13. Shares for $93,232 were sold by Hoeltzel Mary T on Wednesday, August 9.
Investors sentiment decreased to 1.11 in 2017 Q3. Its the same as in 2017Q2. ValuEngine raised Progenics Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Thursday, December 7th. Wells Fargo Mn invested in 208,816 shares. The Massachusetts-based Winslow Evans And Crocker has invested 1.56% in The Home Depot, Inc. (NASDAQ:PGNX). Gru One Trading Limited Partnership holds 0% or 43,990 shares. Zacks Invest Management owns 1,386 shares for 0.01% of their portfolio. (NYSE:HD). Capwealth Limited Liability Corp reported 86,256 shares. Noesis Mangement stated it has 4,025 shares or 0.25% of all its holdings. Clean Yield Grp owns 1,647 shares for 0.13% of their portfolio. Municipal Employees Retirement System of MI grew its position in shares of Progenics Pharmaceuticals by 4.0% during the 2nd quarter. 1,241 are held by Landscape Cap Mgmt Limited Com. Hancock Hldg has 6,130 shares for 0.05% of their portfolio.
Capital International Investors decreased Morgan Stanley (NYSE:MS) stake by 423,400 shares to 789,070 valued at $38.01 million in 2017Q3. State Of Tennessee Treasury Department invested in 139,994 shares. Private Trust Com Na invested in 2,051 shares.
Among 5 analysts covering Progenics Pharm (NASDAQ:PGNX), 5 have Buy rating, 0 Sell and 0 Hold.
Ratings analysis reveals 100% of Progenics Pharm's analysts are positive. It was reported on Jan, 11 by Finviz.com. The firm has "Buy" rating by Brean Capital given on Thursday, August 6.
Progenics Pharmaceuticals, Inc. develops medicines and other technologies to target and treat cancer in the United States and internationally. (NASDAQ:PGNX) rating on Friday, August 7. Needham has "Buy" rating and $11 target. As per Tuesday, January 2, the company rating was maintained by Robert W. Baird. Progenics Pharmaceuticals has a 52-week low of $3.80 and a 52-week high of $10.27. (NASDAQ:PGNX) for 94,652 shares. The rating was upgraded by Needham to "Strong Buy" on Monday, February 6. (NASDAQ:PGNX). Duncker Streett Co has invested 0.03% of its portfolio in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) for 95,088 shares. The rating was initiated by Aegis Capital with "Buy" on Thursday, October 27.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.